| CMBI Fixed Income: Hopson: weaker but much better than peers FY22 results |
| 【Company Research】RemeGen (9995 HK) – Wide clinical studies to unlock global potential |
| 【Company Research】Tigermed (300347 CH) – Targeting the broad global market |
| 【Company Research】Zoomlion (000157 CH) – Surprise on dividend; Potential resumption of A-share repurchase; U/G to BUY |
| 【Company Research】Zoomlion (1157 HK) – Surprise on dividend; Recovery in sight |
| 【Company Research】Dingdang Health (9886 HK) – Long-term growth outlook remains intact |
| 【Company Research】Innovent Biologics (1801 HK) – Revenue growth to recover in 2023 |
| 【Company Research】BYDE (285 HK) – FY22 largely in-line; Gradual recovery on track |
| 【Company Research】Xiabu Xiabu (520 HK) – Both sales and margin recovery are on track |
| 【公司研究】阿里巴巴 (BABA US) – 组织变革或有望助力业务竞争力提升及估值重估 |
Address: 45th & 46th Floor, Champion Tower, 3 Garden Road, Central, Hong Kong
Telephone: （852）3900 0888 Fax:（852）3761 8788
Copyright © 2019-2026 CMB International Capital Corporation Limited. All rights reserved.
